The days of screening a single protein expression profile at a time are coming to an end.
Author: Claire
Editor: tuya
On July 7, Nuclearra, a biotechnology company headquartered in Cambridge, England, announced that it had raised an additional US$15.5 million in Series B financing, bringing the total financing to US$58 million. Nuclera will leverage investments from Jonathan Milner and Verve Ventures to accelerate the commercialization of its core product, the eProtein desktop bioprinter.
To date, Nuclera has received a total of US$83.3 million in financing from investors such as MG, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund and GK Goh.
Historically, developing proteins has been a time-consuming and complex process—it took scientists weeks, months, or even years to obtain the required amount of protein sample.
Nuclera was founded in 2013 and is dedicated to accelerating protein expression workflows. The eProtein bioprinter developed by Nuclera creates a new technology platform based on cell-free protein synthesis and digital microfluidics, which can solve the problem of protein samples within 24 hours and completely Transform the fragmented protein expression screening system to provide a single, optimized, end-to-end workflow for drug discovery and bioinnovation.
eProtein bioprinter will allow researchers to accelerate discovery and treatment processes with desktop access. Researchers will soon be able to move from protein screening to scaled-up protein expression in all niche areas in much faster time.
With desktop bioprinting technology, researchers and scientists can streamline access to next-day protein supplies to control biological development processes.
Nuclera's core product, desktop bioprinter eProtein, currently has 45 patents and 3 core technologies: "eProtein synthetic ink" for protein screening, programmable lab-on-a-chip technology "eDrop digital microfluidics", and high-efficiency enzymatic DNA-based Synthetic polymerase "eDNA synthetic ink".
Jonathan Milner, founder and former CEO of Abcam and CEO of Meltwind Advisory, said, "Rapid protein biomanufacturing technology does not currently exist. The ability to screen multiple protein expression profiles and print purified proteins in 24 hours will revolutionize
As this technology develops, the days of screening single protein expression profiles at a time are coming to an end. .
Nuclera will use the new round of financing to advance product commercialization efforts. In the near future, Nuclera will continue to recruit more personnel in key functional departments to accelerate through the pre-commercial stage and bring some of the key innovative technologies to the market. Customers conduct alpha testing to gather market intelligence and develop full commercial launch plans
